XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.3
Variable Interest Entities - Equity Method Investment - Unconsolidated VIE - Additional Information (Detail) - Beijing Falikang Pharmaceutical Co Ltd
$ in Millions
3 Months Ended
Sep. 30, 2024
USD ($)
Acquisition And Variable Interest Entity [Line Items]  
Dividend received $ 2.2
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | FibroGen Beijing [Member] | AstraZenecaAB [Member]  
Acquisition And Variable Interest Entity [Line Items]  
Percentage of outstanding shares acquired 51.10%